We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Researchers Developing 'Lab-in-Box' Kit for Medium Throughput Processing of COVID-19 Samples for Detection Using RT-PCR

By LabMedica International staff writers
Posted on 10 Nov 2020
A team of scientists is developing viral RNA extraction kits for medium-throughput processing of COVID-19 samples for detection using RT-PCR. More...


Magnostics Ltd. (Dublin, Ireland) is leading a consortium of scientists to develop and launch viral RNA extraction kits for the detection of COVID-19. To detect the SARS-CoV-2 virus, which causes COVID-19 infection, a very small number of RNA viral genomes must be isolated from the nasal swab. This is a stereotypical needle in the haystack problem where there are a very small number of viruses among tens of thousands of much larger cells. The team of scientists has developed necessary protocols for SARS-cov-2 testing based on Magnostics' Si@Hi-Mag superparamagnetic beads. The key is to use Si@Hi-mag magnetic nanoparticles to capture the RNA from the complicated soup that makes up the virus lysate, which includes proteins, lipids, and other cellular components, and then use a powerful magnet to move and thus separate the magnetic nanoparticles. This allows a series of solutions to be used to rinse the RNA-nanoparticle complex and then release the RNA into a buffer that can be used for reverse transcription and quantitative detection with the polymerase chain reaction (PCR).

Using test samples from patients, the team has proven that Si@Hi-mag beads can be used to extract viral RNA from clinical samples. This includes Lysis buffer, which inactivates and bursts open the virus, superparamagnetic nanoparticles, and a rare-earth magnet array for medium-throughput processing. This important demonstration forms the basis for Magnostics to develop a CE marked 'lab-in-box' kit for the medium throughput manual extraction of viral RNA from clinical samples. The product will allow clinical laboratories to perform 400-600 extractions per day using existing infrastructure.

Related Links:
Magnostics Ltd.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The assay evaluates tumor-derived total nucleic acid extracted from CSF and detects multiple biomarker classes (Photo courtesy of Shutterstock)

New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors

Central nervous system (CNS) malignancies pose distinctive diagnostic challenges because tissue-based testing is often infeasible and the blood–brain barrier limits the usefulness of plasma liquid biopsy.... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.